The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Navarro Coy, NC; Brown, S; Bosworth, A; Davies, CT; Emery, P; Everett, CC; Fernandez, C; Gray, JC; Hartley, S; Hulme, C; +8 more... Keenan, AM; McCabe, C; Redmond, A; Reynolds, C; Scott, D; Sharples, LD; Pavitt, S; Buch, MH; (2014) The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC musculoskeletal disorders, 15. p. 452. ISSN 1471-2474 DOI: https://doi.org/10.1186/1471-2474-15-452

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1186/1471-2474-15-452

Abstract

Share

Download

Filename: The Switch study protocol_Gold VoR.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar